BMN-351 in Muscular Dystrophy, Duchenne: NCT06280209 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1/2
Clinical phase
Active, not recruiting
Recruitment status
18
Planned enrollment
2027-04-14
Primary-completion proxy
Executive view
NCT06280209 evaluates BMN-351 in Muscular Dystrophy, Duchenne. The disclosed sponsor is BioMarin Pharmaceutical, Inc., the design is Interventional, and the geographic footprint is Netherlands, Turkey, United Kingdom, Italy, Spain. The first listed primary endpoint is To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters)., assessed over Up to 97 weeks..
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06280209 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Muscular Dystrophy, Duchenne landscape. Drug & Asset MCP drug_fetch was queried for BMN-351, while Company & Deal Intelligence MCP organization_fetch was queried for BioMarin Pharmaceutical, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT06280209 | BMN-351 | Phase 1/2 / Active, not recruiting | BioMarin Pharmaceutical, Inc. | Netherlands, Turkey, United Kingdom, Italy, Spain | To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relation… Up to 97 weeks. | 2027-04-14 |
| NCT06565208 | Forazapadin | Early Phase 1 / Completed | Satellos Bioscience, Inc. | Australia | Incidence and severity of treatment emergent adverse events Part A: Day 1-3; Part B: Day 1-8; Part C: Day 1-3; Part D: Day 1-28 | 2025-04-28 |
| NCT06485661 | Captopril | Early Phase 1 / Unknown status | Ain Shams University | Egypt | The impaired global longitudinal strain will change in echo in the number of participants with duchenne myodystrophy 6 months | 2024-09-30 |
| NCT06450639 | Satralizumab | Phase 2 / Terminated | Hoffmann-La Roche Ltd. | United States, Ukraine, Poland, Denmark, Italy, Spain | Group 2: Change From Baseline to Week 24 in Lumbar Spine (LS) Bone Mineral Density (BMD) Z-score Measured by Dual-energ… Baseline up to Week 24 | 2026-11-18 |
| NCT06392724 | GEN-6050X | Early Phase 1 / Active, not recruiting | Peking Union Medical College Hospital | China | Safety and tolerability of GEN6050X measured by incidence of adverse events (AEs). through 1 year post-treatment | 2025-12-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT06280209 is a Phase 1/2, active, not recruiting study with 18 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters).” over “Up to 97 weeks..” The retrieved endpoint description is: The safety and tolerability of BMN 351 will be assessed based on the incidence of adverse and serious adverse events..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 18 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Muscular Dystrophy, Duchenne. These records do not establish direct evidence for NCT06280209 unless the registration number matches.
Vamorolone for Duchenne Muscular Dystrophy
Phase 2; n=133; TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028); TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028) Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42202243/
Family experience data with delandistrogene moxeparvovec gene therapy treatment for Duchenne muscular dystrophy.
Not Applicable; n=31; Improvement in at least one of the most impactful symptoms = 96.0 % Source: https://download.asgct.org/2026ASGCTAbstractPublication.pdf
Lowering pre-existing immunity to adeno-associated virus-based gene therapy: Pre treatment with imlifidase or plasmapheresis prior to administration of delandistrogene moxeparvove…
Phase 1; n=8; Micro-dystrophin Expression(Week 12) = 21.5 % ( 0.96 - 42.03); Micro-dystrophin Expression(Week 12) = 1.72 % ( 1.46 - 2.11) Source: https://download.asgct.org/2026ASGCTAbstractPublication.pdf
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
BMN-351 is indexed as ASO with DMD exon 51 biology and a global stage of Phase 2. The asset profile lists BioMarin Pharmaceutical, Inc. as an originator or developer.
BioMarin Pharmaceutical, Inc. is indexed in United States with the website http://www.biomarin.com. BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The record lists 19 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether BMN-351 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT06280209
Protocol source: https://clinicaltrials.gov/study/NCT06280209
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
BMN-351 in Muscular Dystrophy, Duchenne is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters). and 2027-04-14 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
